Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody

Table 3 Effects of adalimumab on inflammatory marker, growth and bone health

	Pre adalimumab	Post adalimumab	P value
Inflammation
ΔPCDAI1	15 (-20-55)	-19 (-65-20)	< 0.001
Disease activity2
No disease	2 (11)	6 (33)	NS
Mild	5 (28)	4 (22)	NS
Moderate/severe	6 (61)	8 (45)	NS
Anthropometry1
ΔWeight SDS	-0.2 [1.8- (-2.7)]	0 [1.7-(-1.7)]	NS
ΔHeight SDS	-0.1 [0.7- (-2.5)]	0 [1.3-(-2.5)]	NS
ΔBMI SDS	-0.5 (2.5-2.3)	-0.1 [0.7-(-2)]	NS
Bone density
BMC	0.64 (0.45-0.89)	0.64 (0.46-0.88)	NS
BMD SDS	-1.5 [0-(-3.3)]	-1.8 [0.3-(-3.8)]	NS
BMD SDS < -22	4 (22)	3 (17)	NS
BMAD SDS1	-1.2 [-0.1-(-3.8)]	-1 [-0.2-(-2.8)]	NS
BMAD SDS < -22	3 (17)	3 (17)	NS
Calcium homeostasis1
Albumin corrected Calcium	2.34 (2.06-2.5)	2.29 (1.79-2.49)	NS
Phosphate	1.46 (0.8-1.98)	1.45 (1.22-1.76)	NS
PTH	34.4 (19-66)	41.6 (18-109)	NS
25-OHD	36.4 (10.5-107)	35.5 (7.5-122)	NS
1.25-OHD	65.5 (22-180)	30 (5-165)	NS
Bone markers
Bone alkaline Phosphatase	39 (13-90)	29 (15-57)	NS
Osteocalcin	55 (16-125)	43 (17-90)	NS
C-telopeptide	0.94 (0.2-1.9)	0.8 (0.2-1.1)	NS
Corticosteroids
Children on steroids2	11 (61)	9 (50)	NS
Cumulative dose1	962 (0-3640)	1277 (0-2800)	NS
Daily dose	3.8 (2.5-50)	12.5 (5-50)	NS
Calcium/vitamin D2	8 (44)	10 (55)	NS

¹Results are presented as median (range);

²Results are presented as number (% of total). BMI: Body mass index; PCDAI: Paediatric Crohn’s disease activity index; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; SDS: Standard deviation score; NS: Not significant.